Agenus vs Beam Therapeutics
AGEN and BEAM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and BEAM compare
Beam Therapeutics is the larger company, worth 7.1 times as much as Agenus ($2.2B against $303M).
Beam Therapeutics grew revenue faster over the last twelve months (159% versus 30.5% for Agenus).
Beam Therapeutics scores higher on the StockData Score (9 against 3 for Agenus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | BEAM |
|---|---|---|
| Size and price | ||
| Market cap | $303M | $2.2B |
| Share price | $6.73 | $20.94 |
| Change, 1 year | 51.9% | −3.3% |
| Change, 5 years | −90.4% | −73.4% |
| Beta (5Y) | – | 2.41 |
| Employees | 81 | 511 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 13.9× |
| P/B | – | 2.0× |
| EV/EBITDA | 7.5× | – |
| FCF yield | −32.5% | −17.2% (better) |
| Fair value | – | $23.91 |
| Margin of safety | – | 12.4% |
| Growth | ||
| Revenue growth (TTM) | 30.5% | 159% (better) |
| Revenue growth, 5Y average | 5.3% | 466% (better) |
| Profitability | ||
| Gross margin | 99.5% | – |
| Operating margin | 27.3% (better) | −242% |
| Net margin | – | −54.7% |
| FCF margin | −74.2% (better) | −239% |
| Return on equity | – | −8.1% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Net debt / EBITDA | 0.28 | – |
| Interest coverage | 0.6× | – |
| Current ratio | 0.34 | 14.57 (better) |
| Altman Z-score | −16.50 | 2.36 (better) |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 31.7% | 106% |
| Held by insiders | 6.6% | 3.4% |
| Insider net buying, 12 months | – | −$19.7M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 18.1% | 26.1% |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- BEAM stock overview
- BEAM income statement
- BEAM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.